Hispanopedia Wiki
Articulo de referencia

LY03020

LY03020 is a dual serotonin 5-HT 2C receptor agonist and trace amine-associated receptor 1 (TAAR1) agonist which is under development for the treatment of schizophrenia and Alzh...

Hispanopedia WikiContenido en espanolLectura gratuita

LY03020 is a dual serotonin5-HT2C receptoragonist and trace amine-associated receptor 1 (TAAR1) agonist which is under development for the treatment of schizophrenia and Alzheimer's disease.[1][2][3] It is taken orally as a controlled-release formulation.[1] The drug is under development by Luye Pharma Group.[1][2][3] As of February 2026, it is in phase 1clinical trials for both indications.[1][2][3] The chemical structure of LY03020 does not yet appear to have been disclosed.[1]

See also

References

  1. 123456"LY 03020". AdisInsight. 17 February 2026. Retrieved 27 March 2026.
  2. 123"Delving into the Latest Updates on LPM787000048 with Synapse". Synapse. 9 February 2026. Retrieved 27 March 2026.
  3. 123Sami T (27 March 2026). "Luye advances dual agonist for schizophrenia, Alzheimer's". BioWorld. Retrieved 27 March 2026.
  • Pipeline - Luye Pharma Group